Phase I Study of HBT-708 for Patients With Advanced Solid Tumors
ConditionAdvanced Solid Tumors
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-75
SponsorShenyang Sunshine Pharmaceutical Co., LTD.
About this trial
The purpose of this study will be to evaluate the safety, tolerability, and inital efficacy of HBT-708 in subjects with advanced solid tumors.
Eligibility criteria
Qualifiers
Male or female subjects, age 18 years or older.
Histologically and/or cytologically documented advanced or measurable solid tumors.
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
Life expectancey > = 3 months.
Disqualifiers
Known uncontrolled or symptomatic central nervous system metastatic disease.
Subjects must have recovered (≤ Grade 1 or pretherapy baseline) from AEs due to previously administered therapies. (National Cancer Institute Common terminology Criteria [NCI CTCAE] v.5.0).
Inadequate organ or bone marrow function.
Pregnant or breast-feeding woman.
Trial design
Treatments tested in this trial
- HBT-708
Treatment groups
60 Participants
are divided into 7 treatment groups7
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Source ClinicalTrials.gov